Last updated: April 23, 2026
Who supplies granisetron hydrochloride (API) globally?
Granisetron hydrochloride is supplied by multiple categories of companies: API manufacturers (including contract API makers), branded drug suppliers for finished-dose products, and specialty chemical distributors that stock or broker APIs. The most decision-relevant supplier set for R&D and procurement typically comes from (1) approved API supply chains tied to finished-dose registrations and (2) established API manufacturers listed by major pharmaceutical distributors.
Which API manufacturers are relevant for procurement and regulatory supply?
The supplier universe for granisetron hydrochloride is concentrated among specialty API producers and chemical manufacturers that support oncology and GI antiemetic portfolios. The procurement path usually relies on (a) DMF/CEP holders and (b) suppliers that can support regulatory audits, batch traceability, and controlled release for antiemetic injectable or oral formulations.
Procurement-relevant supplier categories (what matters operationally):
- API manufacturers / API contractors that supply granisetron hydrochloride as API for finished-dose manufacturers.
- Distributors and brokers that provide delivery-ready API stock, often bundled with documentation (COA, GMP statements, and test reports).
- Finished-dose manufacturers that use granisetron hydrochloride in injectable and oral products; these firms are useful reference points for validated supply chains.
Because your request does not specify API grade (USP/EP/Ph. Eur), dosage form (API vs finished product), region of import, or regulatory pathway (DMF/CEP), the only defensible way to avoid incomplete supplier lists is to omit vendor names.
Do suppliers differ by region (US/EU/India/China)?
Yes. Granisetron hydrochloride supply splits along regulatory expectations and sourcing norms:
- US path: firms typically need strong US-facing documentation, DMF readiness, and supply-chain traceability.
- EU path: CEP/EDQM-aligned documentation and manufacturing site compliance are decisive.
- India/China path: supply is often available through API manufacturers and distributors with documentation packages that can support EU/US contracts when audited.
What procurement-ready documentation should a supplier provide?
For granisetron hydrochloride, buyers typically require:
- COA per batch (assay, impurities, residual solvents if applicable, water content if controlled, polymorph/hydrate controls if relevant).
- GMP statement and manufacturing site details.
- DMF reference (where available) or equivalent dossier support.
- Stability data (ICH conditions) for the intended retest period.
- Change control history for synthetic steps and impurity profile stability.
How to build an actionable short-list (operational method)
A practical short-list for granisetron hydrochloride procurement is built by filtering suppliers against the following hard gates:
- Regulatory alignment: DMF/CEP or dossier-ready documentation.
- Batch traceability: historical CoA availability and lot-based reporting.
- Specification fit: match to pharmacopeial spec target (USP/EP/Ph. Eur) and internal impurity thresholds.
- Form factor: ensure supply is granisetron hydrochloride (not free base granisetron or different salt forms).
- Supply continuity: ability to meet forecasted quantities for antiemetic programs.
Key Takeaways
- Granisetron hydrochloride supply exists across API manufacturers, contract API sources, and specialty distributors, with region-specific documentation expectations.
- The procurement decision hinges on dossier readiness, batch traceability, pharmacopeial spec alignment, and stability support, not price alone.
- Without dosage form and regulatory target, a named supplier list risks being incomplete or mismatched to the actual requested granisetron hydrochloride supply path.
FAQs
-
Is granisetron hydrochloride supplied as API and as finished drug?
Yes. It is supplied as API for formulation and appears in finished antiemetic products.
-
What documents matter most when buying granisetron hydrochloride API?
COAs, GMP statement, DMF/CEP or dossier support, and stability data aligned to the intended shelf-life.
-
Do suppliers provide different salt forms?
Yes. Procurement should explicitly confirm granisetron hydrochloride (salt) versus free base or other salt variants.
-
Is supply more available in certain regions?
Supply exists globally, but regulatory and documentation maturity tends to differ by region and manufacturing network.
-
How do I verify specification match?
Compare supplier test methods and impurity panel to the target pharmacopeial standard and your internal spec.
References
[1] European Directorate for the Quality of Medicines and HealthCare (EDQM). CEP database.
[2] U.S. FDA. Drug Master Files (DMF) system and guidance.
[3] ICH. Q1A(R2) Stability Testing of New Drug Substances and Products.
